Australia · Delayed Price · Currency is AUD Orthocell Statistics
Total Valuation
Orthocell has a market cap or net worth of AUD 197.38 million. The enterprise value is 154.40 million.
| Market Cap | 197.38M |
| Enterprise Value | 154.40M |
Important Dates
The next estimated earnings date is Tuesday, October 20, 2026.
| Earnings Date | Oct 20, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Orthocell has 272.25 million shares outstanding. The number of shares has increased by 16.46% in one year.
| Current Share Class | 272.25M |
| Shares Outstanding | 272.25M |
| Shares Change (YoY) | +16.46% |
| Shares Change (QoQ) | +7.69% |
| Owned by Insiders (%) | 14.77% |
| Owned by Institutions (%) | 3.21% |
| Float | 229.52M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 17.30 |
| PB Ratio | 5.74 |
| P/TBV Ratio | 5.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.54 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.97, with a Debt / Equity ratio of 0.03.
| Current Ratio | 5.97 |
| Quick Ratio | 5.61 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -56.82% and return on invested capital (ROIC) is -45.48%.
| Return on Equity (ROE) | -56.82% |
| Return on Assets (ROA) | -25.52% |
| Return on Invested Capital (ROIC) | -45.48% |
| Return on Capital Employed (ROCE) | -39.56% |
| Weighted Average Cost of Capital (WACC) | 3.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.25 |
| Inventory Turnover | 3.26 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.28% in the last 52 weeks. The beta is -0.07, so Orthocell's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | -36.28% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 0.87 |
| Relative Strength Index (RSI) | 40.39 |
| Average Volume (20 Days) | 242,531 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Orthocell had revenue of AUD 11.41 million and -13.91 million in losses. Loss per share was -0.05.
| Revenue | 11.41M |
| Gross Profit | 6.69M |
| Operating Income | -18.38M |
| Pretax Income | -13.91M |
| Net Income | -13.91M |
| EBITDA | -17.52M |
| EBIT | -18.38M |
| Loss Per Share | -0.05 |
Balance Sheet
The company has 43.95 million in cash and 970,192 in debt, with a net cash position of 42.98 million or 0.16 per share.
| Cash & Cash Equivalents | 43.95M |
| Total Debt | 970,192 |
| Net Cash | 42.98M |
| Net Cash Per Share | 0.16 |
| Equity (Book Value) | 34.41M |
| Book Value Per Share | 0.12 |
| Working Capital | 41.46M |
Cash Flow
In the last 12 months, operating cash flow was -12.74 million and capital expenditures -1.11 million, giving a free cash flow of -13.85 million.
| Operating Cash Flow | -12.74M |
| Capital Expenditures | -1.11M |
| Depreciation & Amortization | 863,903 |
| Net Borrowing | -241,490 |
| Free Cash Flow | -13.85M |
| FCF Per Share | -0.05 |
Margins
Gross margin is 58.67%, with operating and profit margins of -161.15% and -121.98%.
| Gross Margin | 58.67% |
| Operating Margin | -161.15% |
| Pretax Margin | -121.98% |
| Profit Margin | -121.98% |
| EBITDA Margin | -153.58% |
| EBIT Margin | -161.15% |
| FCF Margin | n/a |
Dividends & Yields
Orthocell does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.46% |
| Shareholder Yield | -16.46% |
| Earnings Yield | -7.05% |
| FCF Yield | -7.02% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Analyst Forecast
The average price target for Orthocell is 1.14, which is 58.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | 1.14 |
| Price Target Difference | 58.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | 80.38% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |